Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 7Active not recruiting 4Unknown 3Terminated 2Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Breast Neoplasms 1131Neoplasms 986Carcinoma, Non-Small-Cell Lung 902Prostatic Neoplasms 595Neoplasm Metastasis 529Leukemia, Myeloid, Acute 514Colorectal Neoplasms 492Lung Neoplasms 489Melanoma 488Multiple Myeloma 478Pancreatic Neoplasms 387Lymphoma 370Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 348Leukemia 340Leukemia, Lymphocytic, Chronic, B-Cell 322Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 276Carcinoma, Hepatocellular 261Glioblastoma 250Lymphoma, Large B-Cell, Diffuse 244Myelodysplastic Syndromes 243Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

ganitumab 1Receptor Protein-Tyrosine Kinases 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Rhabdomyosarcoma, Alveolar × Clear all
NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
14 enrolled 17 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT00924950 2019-04-18

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

University of California, San Francisco

Phase 4 Terminated
35 enrolled 3 charts
Sarcoma

Psoriasis, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡